Eva Schlein, Johanna Rokka, Luke R. Odell, Sara Lopes van den Broek, Matthias M. Herth, Umberto M. Battisti, Stina Syvänen, Dag Sehlin, Jonas Eriksson
{"title":"将氟-18 标记的四嗪作为 PET 的前靶向成像剂进行合成和评估。","authors":"Eva Schlein, Johanna Rokka, Luke R. Odell, Sara Lopes van den Broek, Matthias M. Herth, Umberto M. Battisti, Stina Syvänen, Dag Sehlin, Jonas Eriksson","doi":"10.1186/s41181-024-00250-6","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The brain is a challenging target for antibody-based positron emission tomography (immunoPET) imaging due to the restricted access of antibody-based ligands through the blood–brain barrier (BBB). To overcome this physiological obstacle, we have previously developed bispecific antibody ligands that pass through the BBB via receptor-mediated transcytosis. While these radiolabelled ligands have high affinity and specificity, their long residence time in the blood and brain, typical for large molecules, poses another challenge for PET imaging. A viable solution could be a two-step pre-targeting approach which involves the administration of a tagged antibody that accumulates at the target site in the brain and then clears from the blood, followed by administration of a small radiolabelled molecule with fast kinetics. This radiolabelled molecule can couple to the tagged antibody and thereby make the antibody localisation visible by PET imaging. The in vivo linkage can be achieved by using the inverse electron demand Diels–Alder reaction (IEDDA), with trans-cyclooctene (TCO) and tetrazine groups participating as reactants. In this study, two novel <sup>18</sup>F-labelled tetrazines were synthesized and evaluated for their potential use as pre-targeting imaging agents, i.e., for their ability to rapidly enter the brain and, if unbound, to be efficiently cleared with minimal background retention.</p><h3>Results</h3><p>The two compounds, a methyl tetrazine [<sup>18</sup>F]MeTz and an H-tetrazine [<sup>18</sup>F]HTz were radiolabelled using a two-step procedure via [<sup>18</sup>F]F-Py-TFP synthesized on solid support followed by amidation with amine-bearing tetrazines, resulting in radiochemical yields of 24% and 22%, respectively, and a radiochemical purity of > 96%. In vivo PET imaging was performed to assess their suitability for in vivo pre-targeting. Time-activity curves from PET-scans showed [<sup>18</sup>F]MeTz to be the more pharmacokinetically suitable agent, given its fast and homogenous distribution in the brain and rapid clearance. However, in terms of rection kinetics, H-tetrazines are advantageous, exhibiting faster reaction rates in IEDDA reactions with dienophiles like trans-cyclooctenes, making [<sup>18</sup>F]HTz potentially more beneficial for pre-targeting applications.</p><h3>Conclusion</h3><p>This study demonstrates a significant potential of [<sup>18</sup>F]MeTz and [<sup>18</sup>F]HTz as agents for pre-targeted PET brain imaging due to their efficient brain uptake, swift clearance and appropriate chemical stability.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"9 1","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-024-00250-6","citationCount":"0","resultStr":"{\"title\":\"Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET\",\"authors\":\"Eva Schlein, Johanna Rokka, Luke R. Odell, Sara Lopes van den Broek, Matthias M. Herth, Umberto M. Battisti, Stina Syvänen, Dag Sehlin, Jonas Eriksson\",\"doi\":\"10.1186/s41181-024-00250-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The brain is a challenging target for antibody-based positron emission tomography (immunoPET) imaging due to the restricted access of antibody-based ligands through the blood–brain barrier (BBB). To overcome this physiological obstacle, we have previously developed bispecific antibody ligands that pass through the BBB via receptor-mediated transcytosis. While these radiolabelled ligands have high affinity and specificity, their long residence time in the blood and brain, typical for large molecules, poses another challenge for PET imaging. A viable solution could be a two-step pre-targeting approach which involves the administration of a tagged antibody that accumulates at the target site in the brain and then clears from the blood, followed by administration of a small radiolabelled molecule with fast kinetics. This radiolabelled molecule can couple to the tagged antibody and thereby make the antibody localisation visible by PET imaging. The in vivo linkage can be achieved by using the inverse electron demand Diels–Alder reaction (IEDDA), with trans-cyclooctene (TCO) and tetrazine groups participating as reactants. In this study, two novel <sup>18</sup>F-labelled tetrazines were synthesized and evaluated for their potential use as pre-targeting imaging agents, i.e., for their ability to rapidly enter the brain and, if unbound, to be efficiently cleared with minimal background retention.</p><h3>Results</h3><p>The two compounds, a methyl tetrazine [<sup>18</sup>F]MeTz and an H-tetrazine [<sup>18</sup>F]HTz were radiolabelled using a two-step procedure via [<sup>18</sup>F]F-Py-TFP synthesized on solid support followed by amidation with amine-bearing tetrazines, resulting in radiochemical yields of 24% and 22%, respectively, and a radiochemical purity of > 96%. In vivo PET imaging was performed to assess their suitability for in vivo pre-targeting. Time-activity curves from PET-scans showed [<sup>18</sup>F]MeTz to be the more pharmacokinetically suitable agent, given its fast and homogenous distribution in the brain and rapid clearance. However, in terms of rection kinetics, H-tetrazines are advantageous, exhibiting faster reaction rates in IEDDA reactions with dienophiles like trans-cyclooctenes, making [<sup>18</sup>F]HTz potentially more beneficial for pre-targeting applications.</p><h3>Conclusion</h3><p>This study demonstrates a significant potential of [<sup>18</sup>F]MeTz and [<sup>18</sup>F]HTz as agents for pre-targeted PET brain imaging due to their efficient brain uptake, swift clearance and appropriate chemical stability.</p></div>\",\"PeriodicalId\":534,\"journal\":{\"name\":\"EJNMMI Radiopharmacy and Chemistry\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-024-00250-6\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Radiopharmacy and Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s41181-024-00250-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Radiopharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s41181-024-00250-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
引用次数: 0
摘要
背景:由于抗体配体通过血脑屏障(BBB)受到限制,因此脑部是抗体正电子发射断层成像(immunoPET)的一个挑战性靶点。为了克服这一生理障碍,我们之前开发了双特异性抗体配体,通过受体介导的转囊作用穿过血脑屏障。虽然这些放射性标记配体具有高亲和力和特异性,但它们在血液和大脑中的停留时间较长(这是大分子的典型特点),这给 PET 成像带来了另一个挑战。一种可行的解决方案是采用两步预靶向方法,即先用标记抗体在脑内靶点聚集,然后从血液中清除,再用具有快速动力学特性的放射性标记小分子。这种放射性标记分子可与标记抗体耦合,从而使 PET 成像显示抗体的定位。体内连接可通过反电子需求 Diels-Alder 反应(IEDDA)实现,反应物为反式环辛烯(TCO)和四嗪基团。本研究合成了两种新型 18F 标记的四嗪化合物,并对其作为预靶向成像剂的潜在用途进行了评估,即评估其快速进入大脑的能力,以及在未结合的情况下以最小的背景滞留有效清除的能力:这两种化合物,一种是甲基四嗪[18F]MeTz,另一种是H-四嗪[18F]HTz,通过在固体支持物上合成[18F]F-Py-TFP,然后与含胺四嗪酰胺化的两步法进行放射性标记,结果放射化学产率分别为24%和22%,放射化学纯度大于96%。进行了体内 PET 成像,以评估它们是否适合用于体内预靶向。PET 扫描的时间-活性曲线显示,[18F]MeTz 是药代动力学上更合适的制剂,因为它在大脑中分布快而均匀,清除迅速。不过,在反应动力学方面,H-四嗪具有优势,在与反式环辛烯等二烯烃的IEDDA反应中表现出更快的反应速率,这使得[18F]HTz可能更有利于预靶向应用:本研究表明,[18F]MeTz 和[18F]HTz 具有高效的脑摄取能力、快速清除能力和适当的化学稳定性,因此具有作为前靶向 PET 脑成像制剂的巨大潜力。
Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET
Background
The brain is a challenging target for antibody-based positron emission tomography (immunoPET) imaging due to the restricted access of antibody-based ligands through the blood–brain barrier (BBB). To overcome this physiological obstacle, we have previously developed bispecific antibody ligands that pass through the BBB via receptor-mediated transcytosis. While these radiolabelled ligands have high affinity and specificity, their long residence time in the blood and brain, typical for large molecules, poses another challenge for PET imaging. A viable solution could be a two-step pre-targeting approach which involves the administration of a tagged antibody that accumulates at the target site in the brain and then clears from the blood, followed by administration of a small radiolabelled molecule with fast kinetics. This radiolabelled molecule can couple to the tagged antibody and thereby make the antibody localisation visible by PET imaging. The in vivo linkage can be achieved by using the inverse electron demand Diels–Alder reaction (IEDDA), with trans-cyclooctene (TCO) and tetrazine groups participating as reactants. In this study, two novel 18F-labelled tetrazines were synthesized and evaluated for their potential use as pre-targeting imaging agents, i.e., for their ability to rapidly enter the brain and, if unbound, to be efficiently cleared with minimal background retention.
Results
The two compounds, a methyl tetrazine [18F]MeTz and an H-tetrazine [18F]HTz were radiolabelled using a two-step procedure via [18F]F-Py-TFP synthesized on solid support followed by amidation with amine-bearing tetrazines, resulting in radiochemical yields of 24% and 22%, respectively, and a radiochemical purity of > 96%. In vivo PET imaging was performed to assess their suitability for in vivo pre-targeting. Time-activity curves from PET-scans showed [18F]MeTz to be the more pharmacokinetically suitable agent, given its fast and homogenous distribution in the brain and rapid clearance. However, in terms of rection kinetics, H-tetrazines are advantageous, exhibiting faster reaction rates in IEDDA reactions with dienophiles like trans-cyclooctenes, making [18F]HTz potentially more beneficial for pre-targeting applications.
Conclusion
This study demonstrates a significant potential of [18F]MeTz and [18F]HTz as agents for pre-targeted PET brain imaging due to their efficient brain uptake, swift clearance and appropriate chemical stability.